U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938073) titled 'Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma' on Nov. 10.
Brief Summary: To find the recommended dose of vorasidenib that can be given to participants with IDH2-mutated iCCA.
Study Start Date: April 29, 2027
Study Type: INTERVENTIONAL
Condition:
IDH2-Mutated Intrahepatic Cholangiocarcinoma
Intervention:
DRUG: Vorasidenib
Give by po
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....